ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck & Co. to cut manufacturing

by Alexander H. Tullo
May 4, 2019 | APPEARED IN VOLUME 97, ISSUE 18

 

Job cuts are ahead for Merck & Co. The drug company has approved a restructuring program meant to streamline its manufacturing and supply network and reduce its global real estate footprint. The company says the program will cost $800 million to $1.2 billion to implement; some 55% of the costs will be cash outlays for employee severance and facility shutdowns. The rest will be noncash expenses such as accelerated depreciation. The company anticipates completing the program by the end of 2023. It expects charges of $500 million this year, $187 million of which were in the first quarter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment